Abstract
Résumé
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyReferences
- Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome.Can J Diabetes. 2013; 37: S8-S11
- Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist.Atheroscler Suppl. 2006; 7: 37-42
- Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update.Am J Med. 2004; 116: 47s-63s
- Diabetes mellitus, fasting glucose, and risk of cause-specific death.N Engl J Med. 2011; 364: 829-841
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.BMJ. 2000; 321: 405-412
- Cause-specific mortality in diabetes: recent changes in trend mortality.Eur J Prev Cardiol. 2012; 19: 374-381
- Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.Circulation. 2006; 113: 791-798
- Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.Diabetes Care. 1993; 16: 434-444
- Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study.Lancet. 2006; 368: 29-36
- Type 1 diabetes, hyperglycaemia, and the heart.Lancet. 2008; 371: 1790-1799
- Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study.PLoS Med. 2012; 9: e1001321
- Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group.Circulation. 2008; 117: 2544-2565
- Concomitant diabetes mellitus and heart failure.Curr Probl Cardiol. 2015; 40: 7-43
- Heart failure prevalence, incidence, and mortality in the elderly with diabetes.Diabetes Care. 2004; 27: 699-703
- Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology.Diab Vasc Dis Res. 2013; 10: 330-336
- Prospective development and validation of a model to predict heart failure hospitalisation.Heart. 2014; 100: 923-929
- Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.Diabetes Care. 2002; 25: 1129-1134
- Does using HbA1c inform diagnosis of diabetes in patients with coronary artery disease?.Eur Heart J. 2015; 36: 1149-1151
- The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.Eur Heart J. 2004; 25: 1880-1890
- A simple strategy for screening for glucose intolerance, using glycated haemoglobin, in individuals admitted with acute coronary syndrome.Diabet Med. 2012; 29: 838-843
- Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology.Eur Heart J. 2015; 36: 1171-1177
The Royal College of Physicians and Surgeons of Canada. Objectives of Training in the Subspecialty of Adult Cardiology, 2010. Available at: http://www.royalcollege.ca/cs/groups/public/documents/document/y2vk/mdaw/∼edisp/tztest3rcpsced000881.pdf. Accessed February 18, 2016.
- Coronary artery revascularization in patients with diabetes mellitus.Circulation. 2013; 128: 1675-1685
- Insulin resistance, hyperglycemia, and atherosclerosis.Cell Metab. 2011; 14: 575-585
- Diabetes and antiplatelet therapy in acute coronary syndrome.Circulation. 2011; 123: 798-813
- Impaired hypoxia-inducible factor (HIF) regulation by hyperglycemia.J Mol Med (Berl). 2014; 92: 1025-1034
- Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases.Curr Pharm Des. 2013; 19: 5695-5703
- Diabetic cardiovascular disease induced by oxidative stress.Int J Mol Sci. 2015; 16: 25234-25263
- Diabetes mellitus, arterial wall, and cardiovascular risk assessment.Int J Environ Res Public Health. 2016; 13
- Insulin resistance and hyperglycaemia in cardiovascular disease development.Nat Rev Endocrinol. 2014; 10: 293-302
- Acute hyperglycemia impairs vascular function in healthy and cardiometabolic diseased subjects: systematic review and meta-analysis.Arterioscler Thromb Vasc Biol. 2015; 35: 2060-2072
- Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways.Am J Physiol Heart Circ Physiol. 2016; 310: H153-H173
- Cardiovascular importance of hyperglycemia and hypoglycemia.Diabetes Care. 2013; 36: S267-S271
- Molecular mechanisms linking diabetes to the accelerated development of atherosclerosis.Can J Diabetes. 2013; 37: 345-350
- Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.Eur Heart J. 2015; 36: 1718-1727
- Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction.Diab Vasc Dis Res. 2015; 12: 234-238
- Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.JACC Heart Fail. 2015; 3: 136-145
- Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.Heart Fail Rev. 2012; 17: 325-344
- Hypoglycemia, Diabetes, and cardiovascular events.Diabetes Care. 2010; 33: 1389-1394
- Proinflammatory and prothrombotic effects of hypoglycemia.Diabetes Care. 2010; 33: 1686-1687
- Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study.Diabetes Care. 2014; 37: 3301-3308
- Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study.Diabetes Care. 2008; 31: 556-561
- Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias.Diabetes Care. 2014; 37: 516-520
- Vessel wall stiffness in type 1 diabetes and the central hemodynamic effects of acute hypoglycemia.Am J Physiol Endocrinol Metab. 2007; 293: E1274-E1279
- Transient atrial fibrillation precipitated by hypoglycemia.Ann Emerg Med. 1990; 19: 565-567
- Pathophysiology of the effects of hypoglycemia on the cardiovascular system.Diabetic Hypoglycemia. 2012; 5: 3-8
- Hypoglycemia from a cardiologist's perspective.Clin Cardiol. 2014; 37: 499-504
- The impact of hypoglycemia on the cardiovascular system: physiology and pathophysiology.Angiology. 2016; 67: 802-809
- Hypoglycaemia: the limiting factor in the glycaemic management of type i and type ii diabetes.Diabetologia. 2002; 45: 937-948
- Hypoglycemia in diabetes.Diabetes Care. 2003; 26: 1902-1912
- Hypoglycemia.Can J Diabetes. 2015; 39: 6-8
- Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications.Nat Rev Endocrinol. 2014; 10: 711-722
- Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group.Am J Med. 1991; 90: 450-459
- Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study.J Clin Endocrinol Metab. 2010; 95: 2240-2247
- Mechanisms of hypoglycemia-associated autonomic failure in diabetes.N Engl J Med. 2013; 369: 362-372
- The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.BMJ. 2010; 340: b4909
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med. 2008; 358: 2560-2572
- Glucose control and vascular complications in veterans with type 2 diabetes.N Engl J Med. 2009; 360: 129-139
- Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med. 2008; 358: 2545-2559
- Severe hypoglycemia and risks of vascular events and death.N Engl J Med. 2010; 363: 1410-1418
- Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis.BMJ. 2013; 347: f4533
- Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4).Diabet Med. 2012; 29: e279-e285
- Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: screening for type 1 and type 2 diabetes.Can J Diabetes. 2013; 37: S12-S15
- Validating the CANRISK prognostic model for assessing diabetes risk in Canada's multi-ethnic population.Chronic Dis Inj Can. 2011; 32: 19-31
- Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.Circulation. 2009; 120: 1640-1645
- Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.Diabetes Care. 2005; 28: 2745-2749
- Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose.Evid Rep Technol Assess (Summ). 2005; : 1-11
- Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Reducing the Risk of Developing Diabetes.Can J Diabetes. 2013; 37: S16-S19
- Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med. 2002; 346: 393-403
- Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.N Engl J Med. 2001; 344: 1343-1350
- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.Lancet. 2002; 359: 2072-2077
- Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.Lancet. 2002; 359: 2140-2144
- The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction.Int J Cardiol. 2010; 145: 259-260
- Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: targets for glycemic control.Can J Diabetes. 2013; 37: S31-S34
- 5. Glycemic targets.Diabetes Care. 2016; 39: S39-S46
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med. 1993; 329: 977-986
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet. 1998; 352: 837-853
- 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008; 359: 1577-1589
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.Lancet. 2010; 376: 419-430
- Intensive glucose control and macrovascular outcomes in type 2 diabetes.Diabetologia. 2009; 52: 2288-2298
- Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: monitoring glycemic control.Can J Diabetes. 2013; 37: S35-S39
- From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.Diabetes. 2009; 58: 773-795
- Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: pharmacologic management of type 2 diabetes.Can J Diabetes. 2013; 37: S61-S68
- Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes–2015 interim update.Can J Diabetes. 2015; 39: 250-252
- Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.Diabetes Obes Metab. 2012; 14: 810-820
- Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes: 2016 interim update.Can J Diabetes. 2016; 40: 193-195
- Alogliptin after acute coronary syndrome in patients with type 2 diabetes.N Engl J Med. 2013; 369: 1327-1335
- Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2015; 373: 232-242
- Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.N Engl J Med. 2013; 369: 1317-1326
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet. 2005; 366: 1279-1289
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.Lancet. 2009; 373: 2125-2135
- Basal insulin and cardiovascular and other outcomes in dysglycemia.N Engl J Med. 2012; 367: 319-328
- Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.N Engl J Med. 2015; 373: 2247-2257
- A multicenter observational study of incretin-based drugs and heart failure.N Engl J Med. 2016; 374: 1145-1154
US Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin, 2016. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm. Accessed April 11, 2016.
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med. 2015; 373: 2117-2128
- The EMPA-REG study: what has it told us? A diabetologist's perspective.J Diabetes Complications. 2016; 30: 1-2
- One Small step for empagliflozin, one giant leap for diabetology.Diabetes Ther. 2015; 6: 405-409
- Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2016; 375: 311-322
Novo Nordisk. Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial, 2016. Available at: https://www.novonordisk.com/bin/getPDF.2007805.pdf. Accessed May 30, 2016.
- Emergency hospitalizations for adverse drug events in older Americans.N Engl J Med. 2011; 365: 2002-2012
- Incretin-based therapies.J Diabetes. 2012; 4: 55-67
- Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors.Diabetes Care. 2015; 38: 1638-1642
- Oral antihyperglycemic agents and renal disease: new agents, new concepts.J Am Soc Nephrol. 2005; 16: S7-S10
- Use of metformin in the setting of mild-to-moderate renal insufficiency.Diabetes Care. 2011; 34: 1431-1437
- EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.Am Heart J. 2011; 162: 620-626
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.J Am Soc Hypertens. 2014; 8: 262-275
- Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: diabetes in the elderly.Can J Diabetes. 2013; 37: S184-S190
- Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: management of acute coronary syndromes.Can J Diabetes. 2013; 37: S119-S123
- Effect of a multifactorial intervention on mortality in type 2 diabetes.N Engl J Med. 2008; 358: 580-591
- Comprehensive cardiovascular risk factor control improves survival: The BARI 2D trial.J Am Coll Cardiol. 2015; 66: 765-773
- 2016 ACC lifelong learning competencies for general cardiologists: a report from the ACC Competency Management Committee.J Am Coll Cardiol. 2016; 67: 2656-2695
Article info
Publication history
Footnotes
See page 374 for disclosure information.